Loading...
•
Sep 30, 2022
NextCure Q3 2022 Earnings Report
NextCure reported third quarter 2022 financial results and discontinued development of NC318 program.
Key Takeaways
NextCure reported its third quarter 2022 financial results, highlighted by the discontinuation of the NC318 program and the extension of the cash runway into mid-2025. The company is focusing on advancing its clinical pipeline, including NC410, NC525, and NC762.
Discontinued clinical development of NC318 based on efficacy data.
Initiated a Phase 1b/2 trial to evaluate NC410 in combination with pembrolizumab in patients with solid tumors.
Filed an Investigational New Drug (IND) application for NC525 and received clearance to proceed with a Phase 1 trial.
Initiated the NC762 expansion trial.
Forward Guidance
NextCure expects that discontinuing NC318 and prioritizing NC410 will extend its cash runway into mid-2025, enabling the company to fund operating expenses and capital expenditures.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...